Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class I · High risk Terminated Initiated Mar 22, 2021 (6 years ago)

TRESIBA FlexTouch (Insulin Degludec)

Class I — High risk. Reasonable probability of serious harm or death.

Why it was recalled

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Cause type: Temperature excursion

The product was stored or shipped outside its labeled temperature range. Heat or freezing can degrade a drug without any visible change, so it may be weaker than labeled. All temperature excursion recalls.

What was recalled

TRESIBA FlexTouch (insulin degludec injection) 100 units/mL (U-100), 3 mL Prefilled Pen, Sample, Rx only, Manufactured by: Novo Nordisk A/S, Bagsvaerd, Denmark, Distributed by: Movo Mordisk Inc., Plainsboro, NJ 08536, NDC 0169-2660-90 (Pen), NDC 0169-2660-97 (Kit)

Affected NDCs 0169-2660-90 0169-2660-97

Compare with the code on your package — it is the most precise check available.

Drug: Insulin Category: Diabetes Medication

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Tresiba
insulin degludec
NDC 00169-2660
100 U/mL Injection, Solution
Subcutaneous
Novo Nordisk Rx
Recalling firm
Novo Nordisk Inc
NDC code
0169-2660-90
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0619-2021 · FDA notice

Treat this as urgent. Class I means FDA judged there is a reasonable probability of serious harm. Find the lot number on your package; if it matches the recalled lots, do not take another dose before you have spoken to your pharmacist or prescriber - today, not next week. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Insulin recalls

See all
Class II · Moderate risk

Myxredlin

CGMP Deviations

Ongoing cGMP deviation Baxter Healthcare Corporation NDC 0338-0126-12 D-0806-2026
Class II · Moderate risk

Admelog

Lack of Assurance of Sterility: Malformed crimped collar seal

Ongoing Sterility / contamination Sanofi-Aventis U.S. LLC NDC 0024-5926-05 D-0575-2023
Class I · High risk

Insulin Glargine

Labeling: Missing label: Label missing from some prefilled pens.

Terminated Labeling / mix-up Mylan Pharmaceuticals Inc NDC 49502-394-71 D-1292-2022
Class I · High risk

Insulin Glargine

Labeling: Missing label on the vial

Terminated Labeling / mix-up Mylan Pharmaceuticals Inc NDC 49502-393-80 D-0845-2022

Other recalls by Novo Nordisk Inc

All 2021 recalls
Class I · High risk

Xultophy 100/3.6

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Terminated Temperature excursion Novo Nordisk Inc NDC 0169-2911-90 D-0623-2021
Class II · Moderate risk

ViCTOZA (liraglutide)

Temperature Abuse: product samples were stored at temperatures below 32* F which is not in accordance with storage requirements that could cause a lack of efficacy and damage to the cartridge and pen-injectors.

Terminated Temperature excursion Novo Nordisk Inc NDC 0169-4060-90 D-0622-2021